CD19-targeted UCAR-T for refractory juvenile dermatomyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial tests a new type of immune cell therapy (UCAR-T) that targets a protein called CD19 to treat children with a severe form of juvenile dermatomyositis that hasn't responded to standard treatments. It aims to calm the overactive immune system and reduce symptoms like muscle weakness and skin rashes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 5 years old or older.
- You have been diagnosed with juvenile dermatomyositis (JDM), a rare autoimmune disease that causes muscle weakness and skin rashes.
- Your JDM has not improved with standard treatments like steroids and at least two other immune-suppressing drugs, or you have severe symptoms such as lung, heart, or gut problems, calcium deposits, or persistent muscle weakness.
- Your heart, kidneys, liver, and lungs are working well enough (based on tests).
- If you are a woman who could become pregnant, you agree to use birth control during the study and for one year after treatment.
- You have not had CAR-T therapy before, and you do not have serious active infections or other major health issues that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This trial tests a treatment using your own immune cells, modified to target a protein called CD19, for children and teens with juvenile dermatomyositis that hasn't gotten better with standard treatments. The goal is to see if this therapy can help calm the inflammation and improve symptoms.
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.